Respiratory and thoracic cancers:

Indications for: Vinorelbine

First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), in combination with cisplatin. As a single agent, for the treatment of patients with metastatic NSCLC.

Adult Dosage:

See full labeling. Give by IV inj over 6–10mins. Monotherapy: 30mg/m2 once weekly. Combination therapy: 25mg/m2 on Days 1, 8, 15, and 22 of a 28-day cycle with cisplatin (100mg/m2) given on Day 1 of each 28-day cycle; or 30mg/m2 once weekly with cisplatin (120mg/m2) given on Days 1 and 29, then every 6 weeks. Dose modifications for toxicities, hepatic impairment: see full labeling.

Children Dosage:

Not established.

Boxed Warning:


Vinorelbine Warnings/Precautions:

Risk of myelosuppression. Monitor for infection, and/or fever; obtain CBCs with differentials prior to each dose. Monitor for new or worsening neuropathy. Discontinue if neurotoxicity ≥Grade 2. Interrupt therapy if evidence of pulmonary toxicity or unexplained dyspnea; permanently discontinue if confirmed interstitial pneumonitis or acute respiratory distress syndrome. Hepatic injury or impairment: assess hepatic function prior to and during treatment. Avoid extravasation. Embryo-fetal toxicity. Advise use of effective contraception during and for 6 months (females) and for 3 months (males w. female partners) after last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 9 days after last dose).

Vinorelbine Classification:

Antimicrotubule agent.

Vinorelbine Interactions:

May be potentiated by CYP3A inhibitors. Increased risk of granulocytopenia with cisplatin.

Adverse Reactions:

Leukopenia, neutropenia, anemia, elevated liver enzymes, nausea, asthenia, constipation, inj site reaction, peripheral neuropathy, vomiting; hepatotoxicity, pulmonary toxicity, bowel obstruction, paralytic ileus.


Formerly known under the brand name Navelbine.

How Supplied:

Contact supplier